DHEA for Male Infertility

Verdict: Unverified: no evidence DHEA treats male infertility

There is no credible evidence that DHEA improves male infertility or sperm quality, and it may even lower sperm count, so it cannot be recommended for this use. Its fertility track record applies to women (ovarian reserve/IVF), not men.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

This claim is graded Unverified (insufficient evidence) because the human trial base for DHEA in male infertility is essentially empty. The only randomized trial touching the male reproductive axis (PMID 15037408) gave 50 or 200 mg/day DHEA to just 11 healthy, non-infertile men for three months; it raised DHEA and LH but produced no change in testosterone, estradiol, or any semen parameter. The authors explicitly warned that longer or higher dosing could be toxic to the reproductive axis. The only other study found (PMID 25735445) was a cross-sectional hormone survey of 94 men with no DHEA arm, so it is at best tangential.

A core problem is an evidence-to-indication mismatch: DHEA's fertility literature is overwhelmingly about women with diminished ovarian reserve undergoing IVF, and cannot be extrapolated to male-factor infertility. No randomized trial in actually infertile or oligospermic men exists, and the major specialty guidelines do not endorse DHEA for this purpose.

Regulators and clinics reinforce caution rather than support. The FDA has approved DHEA (prasterone) only as Intrarosa for postmenopausal painful sex, not for male fertility; the UK classes it as a prescription-only and Class C controlled drug; and WADA bans it as an anabolic agent. Mayo Clinic notes DHEA combined with testosterone may actually cause low sperm count and gynecomastia, a potential harm signal, not a benefit.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.40
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
77%
Broadly consistent
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.396
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative;實際 E7)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men
PMID: 15037408 2004 隨機對照試驗 n = 11
Finding: DHEA administration to healthy men raised DHEA, DHEAS, 3-androstanediol glucuronide and LH levels, but produced NO change in testosterone, estradiol, or semen parameters; authors warned that longer duration or higher doses could exert more toxic changes on the reproductive axis.
🟠 Limited quality Effect size: No measurable effect on semen parameters at 3 months
View on PubMed
Sperm concentration is poorly associated with hypoandrogenism in infertile men
PMID: 25735445 2015 Cross-sectional n = 94
Finding: Sperm concentration (normospermia, oligozoospermia, azoospermia) was not associated with biochemical hypoandrogenism; the study evaluated testosterone status, not DHEA supplementation, and is only tangentially relevant.
🟠 Limited quality Effect size: Not applicable (observational, no DHEA arm)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Intrarosa (prasterone) is the first FDA-approved product containing the active ingredient prasterone, also known as dehydroepiandrosterone (DHEA). source↗
L4b EU EFSA
Against
L4c UK NHS
Against
DHEA is classed as a prescription-only medicine in the UK and is also a Class C controlled drug. source↗
L4d TW TFDA / 衛福部
Against
DHEA(脫氫表雄酮)在台灣屬於藥品列管,不論劑量高低均以藥品管理,須由醫師開立處方;不得作為食品或膳食補充劑販售。 source↗
L4e WHO
Cautious
DHEA is included in the pharmacological class S1 'Anabolic Agents' as an Anabolic Androgenic Steroid, prohibited at all times (in and out of competition) under the World Anti-Doping Code. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Not addressed
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-male-infertility-INT-dehydroepiandrosterone-001 繁體中文版 →